Postmortem analyses have determined a significant upregulation in activated microglia and inflammatory markers in the brains of AD patients, and recent imaging studies have used microglial activation in combination with tau localization as a measure of cognitive decline [46–48, 70]. The gene discussed is MAPT; the disease is Alzheimer disease.